NASDAQ · Financial Statements
Magenta Therapeutics, Inc. (MGTA) Financial Statements
$0.70
NASDAQ: MGTA
Market Cap $42.44M
Overview Financials Dividend
Magenta Therapeutics, Inc. most recently reported annual revenue of $2.0M, a net loss of $162.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2020 2021 2022 2024 2025
Revenue $0 $0 $0 $6.0M $2.0M Operating Profit $-79.0M $-75.0M $-81.0M $-102.0M $-178.0M Net Profit $-69.0M $-66.0M $-72.0M $-85.0M $-162.0M EPS $-1.43 $-1.12 $-23.05 $-21.75 $0.00 Op Margin — — — -1633.7% -8739.3%
Balance Sheet (USD)
Metric 2020 2021 2022 2024 2025
Total Assets $162.0M $190.0M $147.0M $374.0M $531.0M Total Liabilities $18.0M $17.0M $41.0M $22.0M $38.0M Cash $58.0M $132.0M $58.0M $23.0M $51.0M Borrowings $0 $0 $30.0M $1.0M $1.0M
Cash Flow (USD)
Metric 2020 2021 2022 2024 2025
Operating Cash Flow $-64.0M $-60.0M $-67.0M $-78.0M $-129.0M Investing Cash Flow $-11.0M $42.0M $-10.0M $-287.0M $-123.0M Financing Cash Flow $68.0M $90.0M $3.0M $256.0M $280.0M Net Cash Flow $-7.0M $73.0M $-74.0M $-109.0M $28.0M Free Cash Flow $-64.0M $-61.0M $-67.0M $-78.0M $-129.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA 8.58 FCF Yield -307.45% Quick Ratio 29.25 Interest Coverage — Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .